4Moving Biotech, a subsidiary of 4P-Pharma, announces establishing an international Scientific Advisory Board in anticipation of its knee osteoarthritis drug candidate’s phase 2b clinical trial. “With their expertise in clinical study design and regulatory affairs, this high-level scientific advisory board will greatly contribute to the future success of 4P004, reinforcing our pioneering position in developing&hellip
We look forward to seeing you on November 14, 2023 at the Carreau du Temple for the 2nd DeeptechConnect, in the HEALTH Village. An exceptional day dedicated to Deeptech, organized by the SATT Network. The first event to bring together industrialists and investors with startups stemming from French public research. For more information about our&hellip
We are delighted to announce our upcoming BIO-Europe participation from November 6th to 8th in Munich! Roselina Lam, our Business Development and Licensing-in Manager, is attending the event. For more information about our pipeline or to schedule a meeting, contact us through our partnering platform: here
4Moving Biotech completes the recruitment of its Phase I clinical trial in patients with knee osteoarthritis
Our subsidiary, 4Moving Biotech, dedicated to facing the global challenge of knee osteoarthritis, announces that it has reached a significant milestone by completing patient recruitment for its LASARE Phase I clinical trial. The Phase I trial is designed as a multi-center, randomized, double-blind, placebo-controlled study to investigate the safety, tolerability, and pharmacokinetics of intra-articular injection&hellip
We are pleased to announce our company’s participation at CHINA Bio 2023, from September 20 – 21, 2023, in Shanghai, China. Our Chairwoman, Revital Rattenbach, and our CEO, Didier Landais, and Francis Berenbaum, CEO/CMO of our subsidiary, 4Moving Biotech, will attend this event. During the event, Pr. Francis Berenbaum will showcase our subsidiary, 4Moving&hellip
We are delighted to announce the appointment of Didier Landais as the CEO of 4P-Pharma. Didier Landais brings a wealth of experience and strategic leadership to our team. His dynamic vision and profound insights will drive 4P-Pharma into an era of innovation and growth. Find the press release in English here.